A pair of top Wall Street firms aren’t on the same page when it comes to the outlook for Valeant Pharmaceuticals Intl Inc VRX 5.18% senior notes. In a March 21 report, Citi analyst Murali Ganti said that the resignation of CEO Michael Pearson and the addition of Bill Ackman to the board of directors should go a long way in stabilizing the volatile stock. In addition, Citi sees plenty of value in Valeant debt.

“We believe today’s announcements will go some way towards stabilizing sentiment, and despite being cautious on the long road ahead for the company, we reiterate our Buy ratings on all of the company’s maturities of 2022 and inside,” Ganti wrote.

Barclays analyst Shubhomoy Mukherjee isn’t buying it. On March 15, Mukherjee slammed…

Click here to continue reading

Want to learn more about how to profit off the stock market? Or maybe you just want to be able to look sophisticated in front of your coworkers when they ask you what you are reading on your Kindle, and you’d prefer to tell them “Oh, I’m just reading a book about stock market analysis,” rather than the usual “Oh, I’m just looking at pics of my ex-girlfriend on Facebook.” For these reasons and more, check out my book, Beating Wall Street with Common Sense. I don’t have a degree in finance; I have a degree in neuroscience. You don’t have to predict what stocks will do if you can predict what traders will do and be one step ahead of them. I made a 400% return in the stock market over five years using only basic principles of psychology and common sense. Beating Wall Street with Common Sense is now available on Amazon, and tradingcommonsense.com is always available on your local internet!